A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

Trial Profile

A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Lipoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 May 2014 Primary endpoint 'Tumour-volume' has been met as reported in a Biospecifics Technologies Corp media release.
    • 04 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top